HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 22, No 01, January 2018 – Weighing the options       » Scientists close in on origin of SARS       » Chinese researchers map key protein in DNA repair with near-atomic resolution       » Ryzodeg reduces hypoglycaemia in type 2 diabetic fasting patients       » United States cancer drug costs increasing despite competition       » Eating yogurt may help reduce chronic inflammation in women      
BIOBOARD - EUROPE
Simple blood test detects 85% of colorectal cancers and over 50% of polyps

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, has released new data showing that when combining two of its proprietary assays into one test, they can achieve 85% detection rates at 85% specificity for colorectal cancer. The data also shows that Volition's two-assay test can detect more than 50% of precancerous polyps.

Earlier this month, VolitionRx presented preliminary data from a 90 patient independent trial, later confirmed in a further 113 patients, at University Hospital Bonn in Germany. This data demonstrated 75% detection rates at 70% specificity when using a single assay. The Belgian team confirmed these results using the same single assay, but when combining it with another nucleosome biomarker they achieved even better results. They have now analysed 39 patients' samples from the ongoing prospective trial which includes both healthy patients and patients with benign colon disorders.

"This increased detection rate confirms our original hypothesis that combining nucleosomes increases the accuracy of the test," comments Dr. Jake Micallef, Chief Scientific Officer of VolitionRx. "We hope to further increase the sensitivity and specificity by adding more biomarkers and developing a larger panel of nucleosome tests."

Current diagnostic screening practices for colorectal cancer vary globally, from inviting at-risk groups to submit fecal occult blood tests to offering regular investigative colonoscopies. Unfortunately studies show compliance rates of between 30-60% for fecal blood tests, likely due to the uncomfortable nature of the test. Meanwhile, a US study found that less than 40% of people who were offered a colonoscopy screening actually attended.

Encouragingly, uptake of diagnostic blood tests is much higher, with one study showing annual prostate cancer screening compliance at higher than 80%. When VolitionRx's blood test is made publically available, higher uptake could be very likely. Additionally, if the research team continue to identify at least 50% of polyps this could also have vast implications for diagnosing earlier-stage colorectal cancers.

Professor Hans Jorgen Nielsen, Professor of Surgical Oncology at Hvidovre Hospital in Denmark, recently expanded his prospective study evaluating VolitionRx's panel as a colorectal cancer screening tool. He comments, "The 85% detection rate seen in this latest research is on par with rates achieved by fecal occult blood tests. If we could improve screening compliance by offering the public a simple, less intrusive test that is just as accurate, we could detect even more colorectal cancer cases in the earlier stages and survival rates could drastically improve."

This test has the potential to become a global first choice diagnostic tool, replacing fecal occult blood tests and preventing unnecessary colonoscopies around the world. The company hopes to apply for CE mark early next year and FDA approval roughly a year later.

Colorectal cancer is the third most prevalent cancer and fourth most common cause of cancer death worldwide.

Source: PR newswire

Click here for the complete issue.

NEWS CRUNCH  
news Biology of Ageing II - Impactful Interventions
news Separation of conjoined twins presents surgical and ethical challenges for MassGeneral Hospital for Children staff
news MIT Technology Review announces 2018's 10 'Innovators Under 35 Asia'
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Addressing the ageing population / Clinical trials
March:
Nutrition / Women in Science
April:
Digestive health / Intellectual property
May:
Asthma / Dental health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy